Explore the Opportunities at the Fourth International LGMD Conference in Orlando, 2025
The Fourth International Limb Girdle Muscular Dystrophy (LGMD) Conference is set to take place from July 18-21, 2025, at the upscale J.W. Marriott Orlando, Grande Lakes. Organized by The Speak Foundation, this essential conference welcomes individuals affected by LGMD, including patients, caregivers, medical practitioners, researchers, and advocacy groups. Opportunities for networking and learning will abound, making it a perfect venue for all involved in the LGMD community.
The primary aim of the conference is to present and discuss crucial updates on LGMD, specifically regarding diagnostic and medical management approaches, preclinical research developments, and clinical trials. Attendees will have the chance to interact directly with leading experts in the field who will speak on emerging research and treatment alternatives. The conference promises a wealth of knowledge, with dedicated sessions on natural history studies, strategies for independent living, and advocating for the LGMD community.
An integral part of the event will be its breakout sessions, designed to foster community among participants and share valuable insights. Experts will provide guidance on disease management, while peer-to-peer interactions will enrich the experience for attendees, enabling them to share their personal stories and strategies for living well with LGMD.
Recognized figures in the LGMD universe will also be honored during the conference. Awards for Lifetime Achievement and Clinical Excellence will be presented to two distinguished professionals, signifying the event's commitment to appreciating those who have made significant contributions to the field.
Confirmed speakers for this year's conference include prestigious professionals such as Dr. Volker Straub from the University of Newcastle, Dr. Louise Rodino-Klapac of Sarepta Therapeutics, and Dr. Sharon Hesterlee of the Muscular Dystrophy Association (MDA), among others. Their expertise will offer invaluable insights into the latest research and potential future treatments, ensuring that attendees acquire a comprehensive understanding of what’s new in the world of LGMD.
Dr. Douglas Sproule, Chief Medical Officer of ML Bio Solutions, expressed pride in participating within this community, highlighting the impact of such gatherings: "Together, we can make a difference. Witnessing the remarkable growth of the LGMD community with each conference has been truly inspiring."
As advancements continue to emerge in LGMD research and treatment, this conference serves not just as an information hub but as a rallying point for advocacy and community support. Louise Rodino-Klapac, PhD, emphasized the importance of connections and collective learning that events like this foster, which plays a pivotal role in driving change across the LGMD landscape.
The Speak Foundation is particularly thankful for the substantial backing from platinum sponsors who aid in the success of this conference. Sarepta Therapeutics, known for advancing gene therapy solutions for various LGMD subtypes, and ML Bio Solutions, actively developing a small-molecule therapy for LGMD 2I/R9, are standout contributors.
Registration for the conference is currently open. Interested individuals are encouraged to secure their spots and hotel accommodations promptly, as space is limited. Attendees can visit www.internationallgmdconference.com for more information and to register for this significant event.
The Speak Foundation is a nonprofit organization dedicated to supporting individuals living with LGMD and promoting the development of effective treatments. Understanding LGMD is crucial: it comprises a series of muscular dystrophies triggered by mutations in various genes, leading to severe disabilities and potentially life-threatening complications.
The Fourth International LGMD Conference in Orlando represents not just a timeline of progress in medical science but an opportunity for personal connection, hope, and continued advocacy in the dynamic field of muscular dystrophy.
The primary aim of the conference is to present and discuss crucial updates on LGMD, specifically regarding diagnostic and medical management approaches, preclinical research developments, and clinical trials. Attendees will have the chance to interact directly with leading experts in the field who will speak on emerging research and treatment alternatives. The conference promises a wealth of knowledge, with dedicated sessions on natural history studies, strategies for independent living, and advocating for the LGMD community.
An integral part of the event will be its breakout sessions, designed to foster community among participants and share valuable insights. Experts will provide guidance on disease management, while peer-to-peer interactions will enrich the experience for attendees, enabling them to share their personal stories and strategies for living well with LGMD.
Recognized figures in the LGMD universe will also be honored during the conference. Awards for Lifetime Achievement and Clinical Excellence will be presented to two distinguished professionals, signifying the event's commitment to appreciating those who have made significant contributions to the field.
Confirmed speakers for this year's conference include prestigious professionals such as Dr. Volker Straub from the University of Newcastle, Dr. Louise Rodino-Klapac of Sarepta Therapeutics, and Dr. Sharon Hesterlee of the Muscular Dystrophy Association (MDA), among others. Their expertise will offer invaluable insights into the latest research and potential future treatments, ensuring that attendees acquire a comprehensive understanding of what’s new in the world of LGMD.
Dr. Douglas Sproule, Chief Medical Officer of ML Bio Solutions, expressed pride in participating within this community, highlighting the impact of such gatherings: "Together, we can make a difference. Witnessing the remarkable growth of the LGMD community with each conference has been truly inspiring."
As advancements continue to emerge in LGMD research and treatment, this conference serves not just as an information hub but as a rallying point for advocacy and community support. Louise Rodino-Klapac, PhD, emphasized the importance of connections and collective learning that events like this foster, which plays a pivotal role in driving change across the LGMD landscape.
The Speak Foundation is particularly thankful for the substantial backing from platinum sponsors who aid in the success of this conference. Sarepta Therapeutics, known for advancing gene therapy solutions for various LGMD subtypes, and ML Bio Solutions, actively developing a small-molecule therapy for LGMD 2I/R9, are standout contributors.
Registration for the conference is currently open. Interested individuals are encouraged to secure their spots and hotel accommodations promptly, as space is limited. Attendees can visit www.internationallgmdconference.com for more information and to register for this significant event.
The Speak Foundation is a nonprofit organization dedicated to supporting individuals living with LGMD and promoting the development of effective treatments. Understanding LGMD is crucial: it comprises a series of muscular dystrophies triggered by mutations in various genes, leading to severe disabilities and potentially life-threatening complications.
The Fourth International LGMD Conference in Orlando represents not just a timeline of progress in medical science but an opportunity for personal connection, hope, and continued advocacy in the dynamic field of muscular dystrophy.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.